GRI Bio to Participate in the Virtual Investor Closing Bell Series
Provided By GlobeNewswire
Last update: Dec 6, 2024
Live webcast on Thursday, December 12th at 4:00 PM ET
LA JOLLA, CA, Dec. 06, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will participate in the Virtual Investor Closing Bell Series on Thursday, December 12, 2024 at 4:00 PM ET.
Read more at globenewswire.com
